filmov
tv
Risk Assessment in CLL Treatment
Показать описание
For the past fifteen years, Lymphoma & Myeloma has been the premier forum on the latest advances in lymphoma, myeloma, and other plasma cell neoplasms. Over forty internationally recognized leaders in molecular biology, pathology, immunology, translational and clinical research have been involved to provide expertise and guidance on recent developments in the basic science, translational medicine and clinical trials.
This Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphocytic leukemia, lymphoma and Hodgkin’s disease.
In this presentation, Dr. Richard R. Furman discusses risk assessment in the treatment of chronic lymphocytic leukemia (CLL)
A continuing education program is offered as a supplement to this webcast at the following location:
© 2015 Imedex, LLC.
This Congress features an interdisciplinary approach, special lectures, debates and interactive techniques to explore the controversial, the upcoming, and the exciting in myeloma, Waldenstrom’s macroglobulinemia, chronic lymphocytic leukemia, lymphoma and Hodgkin’s disease.
In this presentation, Dr. Richard R. Furman discusses risk assessment in the treatment of chronic lymphocytic leukemia (CLL)
A continuing education program is offered as a supplement to this webcast at the following location:
© 2015 Imedex, LLC.
0:27:28
Risk Assessment in CLL Treatment
0:08:11
Risk Assessment in Newly Diagnosed CLL
0:04:47
Case 3: Risk Assessment And Elderly Patients with CLL
0:03:17
Case 1: Assessing Risk in CLL
0:13:19
IGHV and TP53 Sequencing: Clinical Utility in Chronic Lymphocytic Leukemia (CLL)
0:26:34
Chronic Lymphocytic Leukemia: MRD Updates
0:04:13
MRD Assessment and Treatment Selection in CLL
0:02:43
Outcomes in high-risk CLL patients following fixed-duration treatment with ibrutinib plus venetoclax
0:06:58
Risk Stratification in CLL
0:21:09
Minimal residual disease (MRD) in CLL: Is it clinically relevant?
0:00:58
What is CLL, and does everyone really needs treatment? | Dr. Jeff Sharman | Oncology Brothers #2023
0:24:09
Update on Venetoclax for CLL
0:13:55
Debate: Optimal approach for the management of CLL patients with del(17p) - Novel Agents
0:05:00
CLL: Patient Evaluation and Risk Stratification
0:57:42
Update on CLL/SLL for Newly Diagnosed Patients | LRF Webinars
0:50:25
The latest CLL treatments and therapies with Dr Jan Burger
0:58:11
Crafting the New Treatment Mix in CLL
0:10:14
CLL: The Risk of Richter’s Transformation
0:27:18
Novel Treatment Options in CLL
0:03:41
The CLL Treatment Infection Model: identifying patients with CLL at high risk of infections
0:18:49
Use of Novel Prognostic Markers in Practice for CLL
0:00:57
Unanswered questions in frontline CLL treatment
0:51:26
Updates in CLL - 2023 Best of Hematology Conference
0:11:43
Case 1: Newly Diagnosed CLL, IGHV-Unmutated
Комментарии